Clinical Trial: TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07862647) titled 'TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma' on Sept. 28.

Brief Summary: This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete their standard of care chemotherapy and radiation and after their standard of care chemotherapy and radiation while they are receviing their standard of care adjuvant chemotherapy.

Study Start Date: Oct. 29

Study Type: INTERVENTIONAL

Condit...